D E Furst

发表

Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development.

G Levy, C. T. Viswanathan, C C Peck, 1992, Journal of clinical pharmacology.

Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.

R N Maini, P. Lipsky, F. Breedveld, 2005, Arthritis and rheumatism.

Single dose pharmacokinetics of auranofin in rheumatoid arthritis.

H. Paulus, D. Furst, E. Landaw, 1982, The Journal of rheumatology. Supplement.

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

R N Maini, P. Lipsky, D. M. van der Heijde, 2000, The New England journal of medicine.

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

D. Furst, M. Weinblatt, E. Tindall, 1999, Annals of internal medicine.

Significant changes in serum AST across hepatic histological biopsy grades: prospective analysis of 3 cohorts receiving methotrexate therapy for rheumatoid arthritis.

J. Kremer, D. Furst, M. Weinblatt, 1996, The Journal of rheumatology.

Seronegative and seropositive rheumatoid arthritis: radiographic differences.

K S Berbaum, K. Berbaum, M. Kathol, 1988, Radiology.

Methotrexate for rheumatoid arthritis : suggested guidelines for monitoring liver toxicity

J. Kremer, G. Alarcón, D. Furst, 1994 .

Handling missing data issues in clinical trials for rheumatic diseases.

Weng Kee Wong, W. Wong, D E Furst, 2011, Contemporary clinical trials.